Moderna’s respiratory syncytial virus (RSV) vaccine has demonstrated positive levels of efficacy in older adults throughout a phase 3 trial. The vaccine demonstrated efficacy of 83.7% in the recent ConquerRSV trial.
The vaccine utilises mRNA technology to provide a level of immunity against RSV infection for older adults aged 60 and over.
